681. The use of local and nonlocal priors in Bayesian test‐based monitoring for single‐arm phase II clinical trials. (19th May 2021) Authors: Zhou, Yanhong; Lin, Ruitao; Lee, J. Jack Journal: Pharmaceutical statistics Issue: Volume 20:Number 6(2021) Page Start: 1183 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
682. The win ratio: Impact of censoring and follow‐up time and use with nonproportional hazards. (31st October 2019) Authors: Dong, Gaohong; Huang, Bo; Chang, Yu‐Wei; Seifu, Yodit; Song, James; Hoaglin, David C. Journal: Pharmaceutical statistics Issue: Volume 19:Number 3(2020) Page Start: 168 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
683. Threshold‐free estimation of functional antibody titers of a group B streptococcus opsonophagocytic killing assay. (16th February 2015) Authors: Moraschini, Luca; Passalacqua, Irene; Fabbrini, Monica; Y Ros, Immaculada Margarit; Rigat, Fabio Journal: Pharmaceutical statistics Issue: Volume 14:Number 3(2015:May/Jun.) Page Start: 189 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
684. TITE‐BOIN‐ET: Time‐to‐event Bayesian optimal interval design to accelerate dose‐finding based on both efficacy and toxicity outcomes. (12th December 2019) Authors: Takeda, Kentaro; Morita, Satoshi; Taguri, Masataka Journal: Pharmaceutical statistics Issue: Volume 19:Number 3(2020) Page Start: 335 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
685. TITE‐gBOIN: Time‐to‐event Bayesian optimal interval design to accelerate dose‐finding accounting for toxicity grades. (3rd December 2021) Authors: Takeda, Kentaro; Xia, Qing; Liu, Shufang; Rong, Alan Journal: Pharmaceutical statistics Issue: Volume 21:Number 2(2022) Page Start: 496 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
686. To adjust or not to adjust for baseline when analyzing repeated binary responses? The case of complete data when treatment comparison at study end is of interest. (10th April 2015) Authors: Jiang, Honghua; Kulkarni, Pandurang M.; Mallinckrodt, Craig H.; Shurzinske, Linda; Molenberghs, Geert; Lipkovich, Ilya Journal: Pharmaceutical statistics Issue: Volume 14:Number 3(2015:May/Jun.) Page Start: 262 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
687. To use or not to use propensity score matching?. (10th August 2020) Authors: Wang, Jixian Journal: Pharmaceutical statistics Issue: Volume 20:Number 1(2021) Page Start: 15 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
688. Tobit regression for modeling mean survival time using data subject to multiple sources of censoring. (22nd January 2018) Authors: Gong, Qi; Schaubel, Douglas E. Journal: Pharmaceutical statistics Issue: Volume 17:Number 2(2018) Page Start: 117 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
689. Treatment allocation strategies for umbrella trials in the presence of multiple biomarkers: A comparison of methods. (24th March 2021) Authors: Ouma, Luke Ondijo; Grayling, Michael J.; Zheng, Haiyan; Wason, James Journal: Pharmaceutical statistics Issue: Volume 20:Number 6(2021) Page Start: 990 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
690. Treatment effect measures under nonproportional hazards. (6th October 2022) Authors: Snapinn, Steven; Jiang, Qi; Ke, Chunlei Journal: Pharmaceutical statistics Issue: Volume 22:Number 1(2023) Page Start: 181 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗